Serum Cytokine Profiles of Children with Obsessive-Compulsive Disorder Shows the Evidence of Autoimmunity

Şeref Şimşek, MD; Tuğba Yüksel, MD; Abdullah Çim, PhD; Savaş Kaya, PhD

Department of Child Psychiatry (Drs Şimşek and Yüksel), Department of Medical Genetics (Dr Çim), and Department of Immunology (Dr Kaya), Dicle University, Medical School, Diyarbakır, Turkey.

Correspondence: Şeref Şimşek, MD, Dicle University Medical School, Department of Child Psychiatry, Diyarbakır, Turkey (drserefsimsek@gmail.com).

Abstract

Background: Previous reports have described an association between autoimmunity and primary obsessive compulsive disorder. This study aimed to investigate any differences in the levels of T helper 1, 2, and 17 effector cell cytokines between obsessive compulsive disorder patients and the control group.

Methods: The study included 34 children (23 males, 11 females), aged between 7 and 17 years, with a diagnosis of obsessive compulsive disorder prior to receiving treatment. The control group consisted of age- and gender-matched children. Study participants were assessed using the Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime version, Children’s Yale Brown Obsession Compulsion Scale, and Children’s Depression Inventory. Cytokine serum concentrations were measured using the BD Cytometric Bead Array Human Th1/Th2/Th17 Cytokine Kit.

Results: Interleukin-17A, tumor necrosis factor-α, and interleukin-2 levels were significantly higher in obsessive compulsive disorder patients. However, there was no correlation between T helper 1 and 17 cytokine profiles in the obsessive compulsive disorder group. The duration and severity of obsessive compulsive disorder symptoms were not significantly associated with interleukin-17A, interferon-gamma-γ, interleukin-10, interleukin-6, interleukin-4, and interleukin-2 levels. Interestingly, a negative correlation was found between tumor necrosis factor-α levels and Clinical Global Impression scores.

Conclusions: These findings suggest, in some cases, obsessive compulsive disorder may develop on a background of autoimmunity, and interleukin-2, tumor necrosis factor-α, and interleukin-17A may play a role in these autoimmune processes. Therefore, we believe it is important to investigate for obsessive compulsive disorder symptoms in patients with autoimmune disease and, conversely, autoimmune diseases in obsessive compulsive disorder patients.

Keywords: obsessive compulsive disorder, cytokine, IL-17, autoimmunity, children

Introduction

Obsessive compulsive disorder (OCD) is a chronic disorder with functional impairment characterized by obsessive, unwanted, and repetitive thoughts and/or repetitive ritualistic behaviors (Murphy et al, 2006). The prevalence of OCD is 1%-3% (Heyman et al, 2001), and symptoms start in childhood in approximately 80% of cases (Pauls et al, 1995). The etiologies of OCD are largely multifactorial, involving complex interactions between genetic and environmental factors (Pauls, 2010). Moreover, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome OCD are 2 OCD subtypes in children that are developed secondary to infection due to cross-reactive antibodies (Swedo et al, 2012; Murphy et al, 2014).
Studies performed on pediatric subjects have provided better insight into the mechanism underlying the association of psychiatric disease with inflammation, since there are fewer confounding factors in childhood, such as duration of disease, medication, adverse effects, and comorbidities (McEwen, 2006; Mitchell and Goldstein, 2014). Therefore, the pediatric population represents an optimal study group to identify an underlying inflammatory mechanism in OCD patients (Kapczinski et al., 2008). In addition, cytokine production in children was different from adults (Lilic et al., 1997).

In OCD patients, previous studies have reported irregularities of neurotransmitters, such as glutamate, serotonin, and dopamine, in the cortico-striato-thalamo-cortical circuits (Murphy and Pigott, 1990; Russell et al., 2003; Maina et al., 2008; Pittenger et al., 2011; Rodriguez et al., 2015). It has been shown that specific cytokines may have an effect on the synthesis, release, and reuptake of these neurotransmitters (Miller et al., 2013). For example, interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) have been reported to activate the enzyme indoleamine 2,3 dioxygenase, which decreases brain serotonin levels by consuming tryptophan, the serotonin precursor, via the production of kynurenine and neuroactive metabolites (Dantzer et al., 2008). In turn, neuroactive metabolites might affect the levels of dopamine and glutamate (Miller et al., 2013). Another example described is interleukin (IL)-6. The increased level of IL-6 in the central nervous system has been associated with decreased levels of tetrahydrobiopterin, a cofactor in the synthesis of serotonin and dopamine (Haroon et al., 2012), which, in turn, resulted in decreased levels of serotonin and dopamine (Felger et al., 2013). Furthermore, a mixture of IL-1β, TNF-α, and IFN-γ has been reported to enhance the release of glutamate from astrocytes (Ida et al., 2008).

However, cytokine production in children is different from that in adults. There is evidence of a role of inflammation in neuropsychiatric diseases in both children and adolescents (Mitchell and Goldstein, 2014), but there are inconsistent results from studies investigating cytokine levels in the serum and cerebrospinal fluid in OCD patients. Anomalies in the immune system have been identified in children diagnosed with both tic disorder, for instance, Tourette’s disorder (TD), and OCD (Leckman et al., 2005; Gabbay et al., 2009; Bos-Veneman et al., 2010). Moreover, a meta-analysis of studies of adult OCD patients found reduced levels of IL-1β, but similar levels of IL-6 and TNF-α, compared with patients without OCD. To the best of our knowledge, there have been no studies investigating cytokine profiles in pediatric patients with OCD only (Gray andBloch, 2012).

Although some studies have supported the opposite (Gause et al., 2009), other studies have reported an association between autoimmunity and primary OCD (Pearlman et al., 2014). Studies conducted in both pediatric and adult OCD patients found higher levels of antibasal ganglia antibodies and antithalamic autoantibodies compared with the control group (Dale et al., 2005; Pearlman et al., 2014). In addition, antibasal ganglia antibody was found in both seropositive (antißtreptolysin O-positive) and seronegative OCD patients (Nicholson et al., 2012). Consistent with these findings, functional abnormalities in the cortico-striato-thalamo-cortical circuitry in OCD were also reported (Pittenger et al., 2011).

One way of understanding whether OCD may have an immunologic etiology is to study the cytokine profile of T-helper (Th) cells. Th cells are characterized and classified on the basis of the cytokines they secrete (Raphael et al., 2015). Th cells produce IL-2, IFN-γ, and TNF-α (Ruffell et al., 2010); Th1, effector cells produce IL-4, IL-10, and IL-13 (Agarwal et al., 2010); and Th17, effector cells produce IL-17 (Harrington et al., 2005). Both Th1 and Th17, effector cells play a role in autoimmune diseases (Cosmi et al., 2014; Eyrech and Zielinski, 2014).

To our knowledge, there have been no published studies on the inflammation in children and adolescents with OCD. This study investigated any differences in the levels of IL-17A, TNF-α, IFN-γ, IL-10, IL-6, IL-4, and IL-2 in OCD patients compared with the control group. The study also aimed to determine whether there was an association between cytokine levels and the severity of OCD.

Methods

Study Participants

The study was conducted in the Department of Child Psychiatry at Dicle University Training and Research Hospital between January 2014 and December 2014. A total of 52 children with OCD were admitted during this period, of which only 41 agreed to participate in the study. Seven cases were excluded from the study based on the exclusion criteria. Thus, the study population comprised 34 children, aged between 7 and 17 years (23 males, 11 females), diagnosed with OCD prior to receiving treatment.

Socio-demographic features and clinical data of the participants were recorded by the psychiatrists. A structured psychiatric interview (Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime version [K-SADS-PL] and Children’s Yale Brown Obsession Compulsion Scale [CY-BOC]) was conducted, and self-reported Children’s Depression Inventory (CDI) given to the participants. Height and weights were measured, and the body mass index was calculated.

K-SADS-PL

The K-SADS-PL schedule, originally developed by Kaufman et al. (1997) and adapted to the Turkish version by Gökler et al. (2004) evaluates the presence of common psychopathologies, primarily OCD, in children and adolescents. It was administered as part of the structured psychiatric interview with the parents and children. The final evaluation was performed using input from all data sources.
CY-BOC

The CY-BOC is a semistructured tool to measure the severity of OCD signs within the past week (Scahill et al, 1997). It comprises 5 main sections: instructions, an obsession screening list, items to determine the severity of obsessions, a compulsion screening list, and items to determine the severity of compulsions. Information was gathered from the child and his/her parents. The validity and reliability study of the Turkish version of this scale was carried out by Yucelen et al. (2006).

CDI

The CDI was developed by Kovacs (1985), based on the Beck Depression Scale, and we used the CDI scale adapted in Turkish by Öy (1991). Of note, questions specific to the childhood period, such as school success and relationship with friends, were added. The scale contains 27 items, and each item is scored as “0”, “1”, or “2” points depending on the severity of the symptoms. The maximum score is 54 points. High scores indicate the level or severity of depression. The cutoff point for the scale is 19 points.

Clinical Global Impression Scale

The Clinical Global Impression (CGI) scale is a standardized evaluation tool used to rate disease severity, disease course over time, and drug effects according to the clinical condition of the patient and the severity of the side effects. CGI is rated on a 7-point scale, from 1 (normal) to 7 (severe disease) (Guy, 1976).

Cytokine Bead Array

Blood samples were obtained between 10:00 and 12:00 AM. The samples were collected in gel tubes and stored at 4°C until centrifugation later on the same day. All blood samples were then centrifuged at 5000 rpm for 6 minutes. The sera were transferred to 1.5-mL polystyrene tubes and stored at −80°C for subsequent analysis. The BD Cytometric Bead Array Human Th1/Th2/Th17, Cytokine Kit (cat. no. 560484, BD Biosciences), FCAP Array v3.0 software (23-13454-00, BD Biosciences), and BD FACsVerse system (23-13453-00, BD Biosciences) were used for the measurement and analysis of the concentrations of the cytokines IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ, and TNF-α. Sera were used without dilutions for BD Cytometric Bead Array analysis.

Statistical Analysis

Statistical analysis was performed using SPSS 18.0 software package (SPSS Inc, Chicago, IL). The chi-square test was used to evaluate any difference between the groups in terms of gender, consanguinity between parents, and history of psychiatric disorders. The Student’s t test was used to compare normally distributed variables in independent groups, and the Mann-Whitney test was used to compare nonnormally distributed variables. The effects of age and gender were adjusted using 2-way ANOVA and ANCOVA tests. The Pearson’s test was used to determine correlation coefficients and statistical significance of normally distributed variables, and the Spearman’s test was used for nonnormally distributed variables. P < .05 was considered statistically significant.

Results

There was no significant difference in age or gender between the OCD group (male/female: 23/11; age: 12.8 ± 2.7 years) and the control group (male/female: 17/17; age: 12.8 ± 2.6 years). No differences were detected in the occupation of the parents and the presence of consanguinity between the parents in either group. The frequency of psychiatric diseases in the family and close relatives was significantly higher in the OCD group (P = .00) compared with the control group. The socio-demographic data are shown in Table 1.

No significant difference was found in the depression scores between the OCD and control groups (P = .76). The duration of OCD symptoms was 19.0 ± 19.8 months. Patients reported that the severity of their OCD symptoms had increased to a level that impaired functioning over a mean of 4.0 ± 3.5 months. Data from the psychiatric evaluation using the K-SADS-PL, CY-BOC, and CDI scales are shown in Table 1. IL-17A, TNF-α, and IL-2 levels were significantly higher in OCD patients compared with the control group (P = .03, 0.01, and 0.02, respectively). When 2-way ANOVA and ANCOVA were performed to assess the confounding impact of age and gender on the results, the statistical significance of differences did not change between the OCD

### Table 1. Data Related to Some Sociodemographic Variables and Scales

|                         | OCD (n=34) (mean ± SD) | Control (n=34) (mean ± SD) | z or t Value | P Value |
|-------------------------|------------------------|----------------------------|--------------|---------|
| Age (years)             | 12.8 ± 2.7             | 12.8 ± 2.6                 | t = 0.00     | 1.00    |
| Sex (M/F)               | 23/11                  | 17/17                      | chi-square   | 0.22    |
| Mother’s age (y)        | 42.7 ± 8.2             | 37.4 ± 4.9                 | z = -2.55    | 0.01    |
| Father’s age (y)        | 46.8 ± 4.9             | 42.9 ± 5.8                 | t = 2.12     | 0.04    |
| Consanguineous marriages (yes/no) | 12/22          | 10/24                      | chi-square   | 0.80    |
| History of psychiatric disorders in the family (yes/no) | 20/14              | 2/32                       | chi-square   | 0.00    |
| BMI (kg/m²)             | 19.7 ± 4.1             | 19.7 ± 2.8                 | t = 0.04     | 0.97    |
| CDI                     | 13.3 ± 6.8             | 12.7 ± 6.3                 |              | 0.76    |
| Duration of OCD symptoms (mo) | 19.0 ± 19.8 | NA                         |              |         |
| CY-BOC                  | 12.1 ± 3.4             | NA                         |              |         |
| Obsession               | 10.8 ± 4.1             | NA                         |              |         |
| Total                   | 22.8 ± 7.2             | NA                         |              |         |
| CGI                     | 3.9 ± 0.8              | NA                         |              |         |

Abbreviations: BMI, body mass index; CDI, The Children’s Depression Inventory; CY-BOC, Children’s Yale Brown Obsession Compulsion Scale; CDI*, cutoff point for the scale is 19 points. CGI, Clinical Global Impression Scale; NA, not applicable; OCD, Obsessive Compulsive Disorder.
and control groups in terms of IL-17A, TNF-α, and IL-2 levels (F = 6.547, P = .013; F = 11.175, P = .001; F = 5.109, P = .027, respectively). However, there was no correlation between Th1 and Thα, cytokine profiles in the OCD group. Data from the biochemical analysis are presented in Table 2. The duration and severity of OCD symptoms were not significantly associated with IL-17A, IFN-γ, IL-10, IL-6, IL-4, and IL-2 levels. A negative correlation was found between TNF-α levels and CGI scores (r = -0.46, P = .02).

Discussion

The most important finding of the present study was the significant increase in the levels of the Th1, cytokines IL-2 and TNF-α as well as levels of the Thα, cytokine IL-17 in the OCD group. A further important finding was the lack of correlation between the severity and duration of the OCD symptoms and cytokine levels. Interestingly, a negative correlation was found between disease severity and TNF-α levels.

There are inconsistent results from studies investigating the serum and cerebrospinal fluid levels of cytokines in OCD patients. The IL-2 level has been found higher in children who had TD together with OCD compared with the non-TD TD group, whereas no significant difference has been found in TNF-α and IL-6 levels between the groups. Additionally, a negative correlation has been reported between OCD symptom severity and TNF-α levels (Gabbay et al., 2009). In children with tic disorder, the serum levels of IL-2 have been found to negatively correlate with OCD symptom severity (N. G. Bos-Veneman et al., 2010).

Only one study has investigated IL-2 levels in adult OCD patients and found that levels were similar to those in healthy control subjects (Weizman et al., 1996). A meta-analysis of studies conducted in adult OCD patients found reduced levels of IL-1α and similar levels of IL-6 and TNF-α compared with healthy subjects. Additionally, TNF-α levels were increased in OCD patients who also had depression (Gray and Bloch, 2012).

Consistent with our findings, a study by Leckman et al. reported increased levels of TNF-α in pediatric and adolescent OCD and/or TD patients compared with healthy control subjects (Leckman et al., 2005). The authors also reported a negative correlation between OCD symptom severity and TNF-α levels, also in agreement with our data (Gabbay et al., 2009). Moreover, one report showed that TNF receptor 1 (TNFR1: p55) and TNF receptor 2 (TNFR2: p75) might have opposite effects on neurons, with TNFR1 having a damaging impact on neuronal cells and TNFR2 having a neuroprotective effect (Fontaine et al., 2002). These findings indicate that low TNF-α concentrations may stimulate TNFR1, whereas TNFR2 stimulation may require high TNF-α concentrations. In other words, TNF-α affinity to TNFR1 may be high, but lower to TNFR2. In fact, Frishman et al. (2000) showed that TNF-α affinity to the TNFR2 receptor is 40-fold lower than that to TNFR1. Our findings suggest that high TNF-α levels might ameliorate OCD pathology via TNFR2, whereas low TNF-α levels might contribute to create OCD or make it worse via TNFR1.

On the other hand, Konuk et al. reported that TNF-α levels were higher in patients with childhood-onset OCD than in patients with adult-onset OCD (Konuk et al., 2007). These inconsistencies in findings between pediatric and adult OCD patients might be explained by the variation in cytokine levels by age (Lilic et al., 1997; Geller et al., 2001).

IL-17, the signature cytokine of Thα, cells, has been shown to play a role in the pathogenesis of important psychiatric diseases such as anxiety disorder and TD (Vieira et al., 2010; Cheng et al., 2012). Cheng et al. (2012) found significantly higher IL-17 levels in children and adolescents with TD than in healthy control subjects. Our study was the first to investigate the levels of IL-17A in children and adolescents with OCD, showing significantly higher levels of IL-17A in the OCD group than in healthy controls.

Both Th1 and Thα effector T cells play a role in organ-specific, as well as systemic, autoimmune disease development (Steinman, 2007), while Th effector cells are crucial for allergic diseases (Cosmi L., 2014). Thα cells may show plasticity and can be converted into Th1, or Th effector cells (Cosmi et al., 2014; Ivanova and Orekhov, 2015). Increased levels of TNF-α and IL-17 are associated with numerous autoimmune diseases and blockade of these cytokines have been shown to have therapeutic benefits in various autoimmune diseases (Kodama et al., 2005; Lai and Dong, 2015; Waisman et al., 2015). Our results showed that the levels of the Thα cytokines IL-2 and TNF-α, as well as the levels of the Thα cytokine IL-17A, were significantly higher in the sera of OCD children. However, there was no correlation between Th1 and Th17 cytokine profiles in the OCD group. These findings indicate that the two distinct populations of Th cells, namely Thα and Th1, may play a role in the pathogenesis of OCD.

The present study had some limitations. The cross-sectional study design allowed the measurement of cytokine levels at only a single time point. Also, the small study sample size meant that it was inadequate to be representative of the general population. In addition, we did not assess the antistreptolysin O titration levels.

In conclusion, the present study found significantly higher levels of the Thα cytokines IL-2 and TNF-α, and the Thα cytokine IL-17 in children with OCD. Moreover, there was an inverse correlation between TNF-α levels and disease severity. However, there was no correlation between Th1 and Th17 cytokine profiles in the OCD group. These findings suggest that OCD might be mediated by Thα, or Thα effector T cells, according to serum cytokine profiles. It might be necessary to investigate for OCD symptoms in patients with autoimmunity disease, and conversely for autoimmune diseases in OCD patients. Additionally, the possible effects of adding immunomodulatory and antiinflammatory agents to conventional treatment of OCD should be investigated.

Table 2. Biochemical Parameters in Patients with or without OCD

| Cytokine | OCD (n = 34) (mean ± SD) | Control (n = 34) (mean ± SD) | z or t Value | P Value |
|----------|-------------------------|-----------------------------|--------------|--------|
| IL-17A   | 15.4 ± 26.7             | 2.9 ± 9.9                   | z = -2.18    | 0.03   |
| IFN-γ    | ND                      | 1.04 ± 6.07                 | z = -1.00    | 0.32   |
| TNF-α    | 22.7 ± 32.1             | 4.9 ± 5.6                   | z = 2.63     | 0.01   |
| IL-10    | 6.9 ± 4.6               | 7.1 ± 4.2                   | z = -0.25    | 0.81   |
| IL-6     | 6.8 ± 18.1              | 4.0 ± 9.3                   | z = 1.09     | 0.33   |
| IL-4     | 33.1 ± 12.3             | 28.6 ± 4.6                  | t = 1.96     | 0.06   |
| IL-2     | 21.4 ± 9.0              | 15.8 ± 10.5                 | t = 2.34     | 0.02   |

Abbreviations: ND, not detected; OCD, Obsessive Compulsive Disorder.

Acknowledgments

We thank Dr. Hüseyin Aktaş and Dr. Rümeysa Alaca and our patients and their parents for taking part in this study.

Interest Statement

None.

References

Agarwal A, Agrawal U, Verma S, Mohanty NK, Saxena S (2010) Serum Th1 and Th2 cytokine balance in patients of superfi-
clinical transitional cell carcinoma of bladder pre- and post-intra-
vessel combination immunotherapy. Immunopharmacol Immunotoxicol 32:348–356.
Baune B, Camara M-L, Eyre H, Jawahar C, Anscomb H, Körner H (2012) Tumor necrosis factor-alpha mediated mechanisms of cognitive dysfunction. Transl Neurosci 3:263–277.
Bhattacharyya S, Khanna S, Chakrabarty K, Mahadevan A, Christopher R, Shankar SK (2009) Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. Neuropsychopharmacol Biol Psychiatry 34:2489–2496.
Bos-Veneman NG, Bijzet J, Limburg PC, Minderaa RB, Kallenberg CG, Hoeckstra PJ (2010) Cytokines and soluble adhesion molecules in children and adolescents with a tic disorder. Prog Neuropsychopharmacol Biol Psychiatry 34:1390–1395.
Cheng Y, Zheng Y, He F, Yang J, Li W, Wang M, Cui D, Chen Y (2012) Detection of autoantibodies and increased concentrations of interleukins in plasma from patients with Tourette’s syndrome. J Mol Neurosci 48:219–224.
Cosmi L, Maggi L, Santarlasci V, Liotta F, Annunziato F (2014) T helper cells plasticity in inflammation. Cytometry Part A 85:36–42.
Dale RC, Heyman I, Giovannoni G, Church AWJ (2005) Incidence of anti-brain antibodies in children with obsessive-compulsive disorder. Br J Psychiatry 187:314–319.
Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56.
Eyerich S, Zielinski CE (2014) Defining Th-cell subsets in a classical and tissue-specific manner: Examples from the skin. Eur J Immunol 44:3475–3483.
Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisil U (2002) Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 22:1–7.
Frishman JJ, Edwards CK, Sonnenberg MG, Kohno T, Cohen AM, Dinarello CA (2000). Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. J Infect Dis 182:1722–1730.
Gabbay V, Coffey BJ, Cuttman LE, Gottlieb L, Katz Y, Babb JS, Hamamoto MM, Gonzalez CJ (2009) A cytokine study in children and adolescents with Tourette’s disorder. Prog Neuropsychopharmacol Biol Psychiatry 33:967–971.
Gause C, Morris C, Vernekar S, Pardo-Villamizar C, Grados MA, Singer HS (2009) Antineuronal antibodies in OCD: comparisons in children with OCD-only, OCD+chronic tics and OCD+PANDAS. J Neuroimmunol 218:114–128.
Geller DA, Biederman J, Faroane S, Agranat A, Cradock K, Hagermoser L, Kim G, Frazier J, Coffey BJ (2001) Developmental aspects of obsessive compulsive disorder: findings in children, adolescents, and adults. J Nerv Ment Dis 189:471–477.
Göker B Ünal F, Pehlivan turbo B Kultur EC, Akdemir D Tuner Y (2004) Reliability and validity of Schedule for Affective Disorders and Schizophrenia for School Age Children-Present and Lifetime Version-Turkish Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988.
Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N (1997) Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988.
Kodama S, Davis M, Faustman DL (2005) The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanism-based hypothesis. Cell Mol Life Sci CMLS 62:1850–1862.
Konuk N, Tekin IO, Öztürk U Atik, L Atasoy N, Bektas S, Erdoğan A (2007) Plasma Levels of Tumor Necrosis Factor-Alpha and Interleukin-6 in Obsessive Compulsive Disorder. Mediators Inflamm 2007:1–5.
Kovacs M (1985) The Children’s Depression Inventory (CDI). Psychopharmacol Bull 21.
Lai Y, Dong C (2015) Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int Immunol doi:10.1093/intimm/dxv063.
Leckman JF, Katsovich L, Kawikova I, Lin H, Zhang H, Kronig H, Morshed S, Parveen S, Grantz H, Lombroso PJ, King RA (2005) Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette’s syndrome. Biol Psychiatry 57:667–673.
Lilic D, Cant AJ, Abinun M, Calvert JF, Spickett GP (1997) Cytokine production differs in children and adults. Pediatr Res 42:237–240.
Maggi L, Santarlasci V, Capone M, Rossi MC, Querci V, Mazzoni A, Cimaz R, De Palma R, Liotta F, Maggi E, Romagnani S, Cosmi L, Annunziato F (2012) Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells. Eur J Immunol 42:3180–3188.
Maina G, Pessina E, Albert U, Bogetto F (2008) 8-week single-blind, randomized trial comparing risperidone versus olanzapine for treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol 18:364–372.
Miller AH, Haroon E, Raison CL, Felger JC (2013) Cytokine Targets in the Brain: Impact on Neurotransmitters and Neurocircuits. Depress Anxiety 30:297–306.
Mitchell RB, Goldstein BI (2014) Inflammation in Children and Adolescents With Neuropsychiatric Disorders: A Systematic Review. J Am Acad Child Adolesc Psychiatry 53:274–296.
Murphy TK, Sajid MW, Goodman WK (2006) Immunology of Obsessive-Compulsive Disorder. Psychiatr Clin North Am 29:445–469.
Murphy TK, Gerardi DM, Leckman JF (2014) Pediatric Acute-Onset Neuropsychiatric Syndrome. Psychiatr Clin North Am 37:353–374.
Murphy DL, Pigott TA (1990) A comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety. J Clin Psychiatry 51:53–58.

Nicholson TR, Ferdinando S, Krishnaiah RB, Anhoury S, Lennox BR, Mataix-Colís D, Cleare A, Veale DM, Drummond LM, Fineberg NA (2012) Prevalence of anti-basal ganglia antibodies in adult obsessive-compulsive disorder: cross-sectional study. Br J Psychiatry 200:381–386.

Oy B (1991) The Children’s Depression Inventory: validity and reliability study. Turk J Psychiatry 132–136.

Pauls DL (2010) The genetics of obsessive-compulsive disorder: A review. Dialogues Clin Neurosci 12:149–163.

Pauls DL, Alsobrook JP, Goodman W, Rasmussen S, Leckman JF (1995) A family study of obsessive-compulsive disorder. Am J Psychiatry 152:76–84.

Pearlman DM, Vora HS, Marquis BG, Najjar S, Dudley LA (2014) Anti-basal ganglia antibodies in primary obsessive-compulsive disorder: systematic review and meta-analysis. Br J Psychiatry 205:8–16.

Pittenger C, Bloch MH, Williams K (2011) Glutamate abnormalities in obsessive-compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther 132:314–332.

Raphael I, Nalawade S, Eagar TN, Forsthuber TG (2015) T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 74:5–17.

Rodriguez CI, Kegeles LS, Levinson A, Ogden RT, Mao X, Milak MS, Vermes D, Xie S, Hunter L, Flood P (2015) In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: proof of concept. Psychiatry Res Neuroimaging 233:141–147.

Ruffell B, DeNardo DG, Affara NI, Coussens LM (2010) Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev 21:3–10.

Russell A, Cortese B, Lorch E, Ivey J, Banerjee SP, Moore GJ, Rosenberg DR (2003) Localized Functional Neurochemical Marker Abnormalities in Dorsolateral Prefrontal Cortex in Pediatric Obsessive-Compulsive Disorder. J Child Adolesc Psychopharmacol 13:31–38.

Scanhil L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, Cicchetti D, Leckman JF (1997) Children’s Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 36:844–852.

Steinman L (2007) A brief history of Th17, the first major revision in the Th1/Th2 hypothesis of T cell-mediated tissue damage. Nat Med 13:139–145.

Swedo ES (2012) From Research Subgroup to Clinical Syndrome: Modifying the PANDAS Criteria to Describe PANS (Pediatric Acute-onset Neuropsychiatric Syndrome). Pediatr Ther 2:113.

Vieira MMM, Ferreira TB, Pacheco PA, Barros PO, Almeida CRM, Araújo-Lima CF, Silva-Filho RG, Hygino J, Andrade RM, Linhares UC, Andrade AFB, Bento CAM (2010) Enhanced Th17 phenotype in individuals with generalized anxiety disorder. J Neuroimmunol 229:212–218.

Weizman A, Hauptmann J, Regen T (2015) The role of IL-17 in CNS diseases. Acta Neuropathol 129:625–637.

Weizman R, Laor N, Barber Y, Hermesh H, Notti I, Djaldetti M, Bessler H (1996) Cytokine production in obsessive-compulsive disorder. Biol Psychiatry 40:908–912.

Yirmiya R, Goshen I (2011) Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun. 25:181–213.

Yucelen AG, Rodopman-Arman A, Topcuoglu V, Yazgan MY, Fisek G (2006) Interrater reliability and clinical efficacy of Children’s Yale-Brown Obsessive-Compulsive Scale in an outpatients setting. Comprehensive Psychiatry 47:48–53.